AzTrials
AzTrials

OverweightNCT01665742

Anti-inflammatory Dietary Intervention in Overweight and Obese Adolescents

A study testing Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene in people with Overweight and Obesity, run by University College Dublin at 3 sites in Ireland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The number of overweight and obese children has increased in Ireland at a greater rate than worldwide trends. The poor eating patterns that drive adolescent obesity leads to an increase in the number of unhealthy inflammatory hormones and fats circulating in the blood which increase an adolescent's risk of developing… Read more about this study

Who is it for?
Ages 13 to 18 years
Conditions the study is for
Overweight, Obesity
What is being tested?
Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
58 participants
Where
3 sitesIreland
Study dates
Jan 2012to Nov 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Male or female
  • 13-18 years
  • Body mass index ≥ 91st percentile on UK growth reference charts (Cole, 1995)
  • Medications/dietary supplements which do not interfere with the intervention are allowed, on condition that the participants adhere to the same regimen during the intervention, including oral contraceptives and other non-fatty acid based dietary supplements (e.g. garlic)
  • Smoker or non-smoker
  • Not participating in any other intervention study

Who cannot join

  • Pregnancy or lactation
  • Endocrine disorders such as Polycystic Ovary Syndrome
  • Currently on treatment for a chronic inflammatory condition such as asthma
  • Kidney or liver dysfunction
  • Iron deficiency anaemia
  • Prescribed anti-inflammatory medication
Show all 12Show fewer
  • Consumers of fatty acid supplements including fish oils, evening primrose oil and antioxidant vitamin (A, C, E, -carotene) supplements
  • High consumers of oily fish (> 2 servings/week)
  • Participants planning to start a special diet or lose weight (e.g. Slimfast, Atkins etc)
  • Weight change ≥3kg within the last 3 months
  • Alcohol or drug abuse (based on clinical judgement)
  • Participants with an allergy to fish and/or shellfish

Trial locations and contacts

3 sites in 1 country.

Ireland3 sites
  • Adelaide and Meath Hospital, Incorporating the National Children's Hospital Dublin,

    Dublin

  • Trinity Centre for Health Sciences, St, James's Hospital

    Dublin

  • University College Dublin

    Dublin

Other trials in Ireland

About this study

Official title: Novel Anti-inflammatory Dietary Intervention to Improve the Metabolic Phenotype of Overweight and Obese 13-18 Year Old Adolescents - Insights Into Potential Genetic Susceptibility

The number of overweight and obese children has increased in Ireland at a greater rate than worldwide trends. The poor eating patterns that drive adolescent obesity leads to an increase in the number of unhealthy inflammatory hormones and fats circulating in the blood which increase an adolescent's risk of developing diabetes and heart disease later in life. Dietary patterns have changed whereby key nutrients that are found in fruit, vegetables and fish, which are known to have beneficial effects and reduce risk of obesity and diabetes in later life, may need to be replaced. This project will determine whether a key anti-inflammatory nutrient supplement taken for 8 weeks will improve the metabolic profile of adolescents aged 13-18 years old. Detailed cellular analysis will determine the cellular and molecular mechanisms to provide a thorough explanation of the health effects of this intervention.

Read the detailed description

The emerging model of obesity and diabetes is characterised by sub-acute chronic inflammation and insulin resistance. Mechanistic data indicates inflamed adipose tissue with increased infiltration of immune cells that generate pro-inflammatory cytokines. With childhood obesity in Ireland increasing at a rapid pace, it is important to establish the role of a non-pharmacological dietary approach to decreasing the sub-acute chronic inflammation seen in overweight and obese children. Several foods contain nutrients that are known to have anti-inflammatory properties. Such foods including fish, fruits and vegetables are known to be deplete in the adolescent diet. The aim of this project is to investigate whether a nutritional supplement containing anti-inflammatory nutrients, n-3 polyunsaturated fatty acids (found in fish oil), vitamin C, vitamin E, and polyphenols found in green tea and tomato; will improve metabolic phenotype in 13-18 year old teenagers over an 8-week period. Further, to provide insight into the role of genetics in the development of metabolic dysregulation and response to dietary treatment.

Conditions
Overweight, Obesity
Being tested
Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene, Placebo supplement
Keywords
Obesity, Chronic inflammation, Anti-inflammatory dietary intervention, Genetic susceptibility
Medical subject headings
Overweight, Obesity, Genetic Predisposition to Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopeneDietary supplement

    1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks

    AND

    4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks

    in conjunction with a weight management programme

  • Placebo supplementDietary supplement

    1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks

    AND

    4 x film-coated placebo tablets daily for 8 weeks

    in conjunction with a weight management programme

Study groups in NCT01665742
Study groupRoleWhat they receive
Anti-inflammatory supplementActive comparator8-weeks of daily supplementation with: 1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene in conjunction with a weight management programme
Receives: Dietary Supplement: Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene
Placebo supplementPlacebo comparator8 weeks of daily supplementation with: 1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets in conjunction with a weight management programme
Receives: Dietary Supplement: Placebo supplement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Homeostasis model of assessment - insulin resistance

    Homeostasis model of assessment - insulin resistance (HOMA-IR) will be derived from fasting glucose and insulin concentrations [(fasting plasma glucose x fasting serum insulin)/22.5] as determined by Matthews et al., 1985

    Measured: 8 weeks

Secondary outcomes (5)
  1. Adiponectin

    Adiponectin, a marker of insulin sensitivity, will be determined pre- and post-intervention.

    Measured: 8 weeks

  2. Markers of inflammation

    Markers of inflammation such as C reactive protein, interleukin (IL) - 6, IL-1β, tumour necrosis factor alpha, intra-cellular adhesion molecule-1, vascular cell adhesion molecule-1, retinol binding protein 4, fibrinogen, white blood cells and related inflammatory markers

    Measured: 8 weeks

  3. Lipid Profile

    Full lipid profile and lipidomic analyses (total triacylglycerol, non-esterified fatty acids, total cholesterol, LDL cholesterol, HDL cholesterol and plasma fatty acid composition, diglycerides, cholesterol esters and sphingomyelins,) and related lipid markers

    Measured: 8 weeks

  4. Inflammatory genetic variants

    Inflammatory genetic variants such as complement component 3, lymphotoxin- α, IL-6, IL-1β, TNF-α, adiponectin polymorphisms and related variants that link to the inflammatory phenotype

    Measured: 8 weeks

  5. Functional molecular analysis (ex-vivo)

    Functional molecular analysis will be conducted to determine which insulin sensitising pathways have been modulated by the intervention

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2012 (estimated)
  2. Study startJan 2012
  3. Primary completionNov 2013
  4. Study completionNov 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
58 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01665742
Sponsor's protocol ID
TNS-5
Status last verified
Dec 2014
First submitted
12 Aug 2012
Last updated
9 Dec 2014
Results posted
No
Data monitoring committee
No

Publications

  • McMorrow AM, Connaughton RM, Magalhaes TR, McGillicuddy FC, Hughes MF, Cheishvili D, Morine MJ, Ennis S, Healy ML, Roche EF, Tremblay RE, Szyf M, Lithander FE, Roche HM. Personalized Cardio-Metabolic Responses to an Anti-Inflammatory Nutrition Intervention in Obese Adolescents: A Randomized Controlled Crossover Trial. Mol Nutr Food Res. 2018 May;62(10):e1701008. doi: 10.1002/mnfr.201701008.

    PubMed 29665620

Questions about this trial

What is this clinical trial studying?

A study testing Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene in people with Overweight and Obesity, run by University College Dublin at 3 sites in Ireland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Homeostasis model of assessment - insulin resistance (time frame: 8 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01665742, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2014; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in